Related Experiment Video
Updated: Jun 4, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer
Kristoph Jahnke1, Ulrich Keilholz, Diana Lüftner
1Department of Hematology and Oncology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. kristoph.jahnke@charite.de
Background:
A randomized phase II trial was conducted to determine if two non-platinum protocols are able to yield a similar efficacy and toxicity profile as compared to two platinum-based doublets in advanced non-small cell lung cancer (NSCLC).
Patients And Methods:
A total of 61 patients were randomly assigned to a reference regimen of carboplatin and paclitaxel (repeated every 3 weeks) or to one of three experimental regimens: paclitaxel plus vinorelbine (repeated every 3 or 4 weeks) and carboplatin plus paclitaxel (repeated every 4 weeks).
Results:
The objective remission rate for all the patients was 34.1%. The median progression-free survival for all the patients was 3 months. The median overall survival and one-year overall survival were 6 months and 21.5%, respectively. Toxicity was moderate and manageable. Response, survival and toxicity did not significantly differ between the four treatment groups.
Conclusion:
The efficacy and toxicity profile of platinum-free combinations is comparable to that of platinum-based doublets.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers